文献速递腹部泌尿生殖MR

LI-RADS M与LI-RADS 4/5分类的混合型肝细胞-胆管癌风险分层:MR影像特征与临床病理因素的预后价值

Risk stratification of LI-RADS M and LI-RADS 4/5 combined hepatocellular cholangiocarcinoma: prognostic values of MR imaging features and clinicopathological factors.
PubMed 文献 · Eur Radiol · 2022-03-22

该回顾性研究纳入2015年6月至2020年11月在本机构手术确诊的131例单发原发性混合型肝细胞-胆管癌患者,评估术前MR影像特征与临床病理因素对LI-RADS M和LI-RADS 4/5患者复发风险的分层价值。LI-RADS M组中晕环强化、延迟中心强化和微血管侵犯是RFS的预测因素,LI-RADS 4/5组中马赛克结构、CA19-9和微血管侵犯与RFS独立相关;据此分层后四组中位RFS分别为25.6、8.2、51.7和18.1个月。

要点

  • LI-RADS M的cHCC-CCA中,晕环强化、延迟中心强化和微血管侵犯预测无复发生存。
  • LI-RADS 4/5的cHCC-CCA中,马赛克结构、CA19-9和微血管侵犯与无复发生存独立相关。
  • 按独立预测因素数目分层后,四亚组中位RFS分别为25.6、8.2、51.7和18.1个月。

核心结论

  • 研究探讨了影像和临床病理因素对LR-M和LR-4/5的cHCC-CCA患者的预后价值,风险分层后四个亚组间观察到不同的生存结局。

研究设计与样本

  • 回顾性识别2015年6月至2020年11月在本机构手术后确诊为cHCC-CCA的连续患者,最终纳入131例符合2019 WHO分类标准的单发原发性病灶患者;两名放射科医师独立评估术前MR影像特征并为每个病灶分配LI-RADS类别,同时收集术前临床数据。

关键影像表现/征象

  • LI-RADS M组中,晕环强化、延迟中心强化和微血管侵犯被确定为无复发生存(RFS)的预测因素。
  • LI-RADS 4/5组中,马赛克结构、CA19-9和微血管侵犯与RFS独立相关。
  • 根据这些独立预测因素的数目,患者被分层为预后良好组(LR-ML亚组和LR-4/5L亚组)和预后不良组(LR-MH亚组和LR-4/5H亚组)。

诊断标准与关键数值

  • LR-ML、LR-MH、LR-5L和LR-5H对应的中位RFS分别为25.6个月、8.2个月、51.7个月和18.1个月。
  • 采用多因素Cox比例风险模型分别识别与LR-M和LR-4/5的cHCC-CCA复发相关的独立因素。
  • 采用Kaplan-Meier生存曲线和log-rank检验分析无复发生存率和总生存率。

临床应用与阅片要点

  • 对于LI-RADS M的cHCC-CCA患者,阅片时可关注晕环强化和延迟中心强化,并结合微血管侵犯进行风险分层。
  • 对于LI-RADS 4/5的cHCC-CCA患者,阅片时可关注马赛克结构,并结合CA19-9和微血管侵犯进行风险分层。
  • 部分LR-M的cHCC-CCA患者RFS和OS并不总是比LR-4/5患者差。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: To investigate the role of clinicopathological factors and MR imaging factors in risk stratification of combined hepatocellular cholangiocarcinoma (cHCC-CCA) patients who were classified as LR-M and LR-4/5.

METHODS: We retrospectively identified consecutive patients who were confirmed as cHCC-CCA after surgical surgery in our institution from June 2015 to November 2020. Two radiologists evaluated the preoperative MR imaging features independently, and each lesion was assigned with a LI-RADS category. Preoperative clinical data were also collected. Multivariate Cox proportional hazards model was applied to separately identify the independent factors correlated with the recurrence of cHCC-CCAs in LR-M and LR-4/5. Risk stratifications were conducted separately in LR-M and LR-4/5. Recurrence-free survival (RFS) rates and overall survival (OS) rates were analyzed by using the Kaplan-Meier survival curves and log-rank test.

RESULTS: A total of 131 patients with single primary lesion which met the 2019 WHO classification criteria were finally included. Corona enhancement, delayed central enhancement, and microvascular invasion (MVI) were identified as predictors of RFS in LR-M. Mosaic architecture, CA19-9, and MVI were independently associated with RFS in LR-4/5. Based on the number of these independent predictors, patients were stratified into favorable-outcome groups (LR-ML subgroup and LR-4/5L subgroup) and dismal-outcome groups (LR-MH subgroup and LR-4/5H subgroup). The corresponding median RFS for LR-ML, LR-MH, LR-5L, and LR-5H were 25.6 months, 8.2 months, 51.7 months, and 18.1 months.

CONCLUSION: Our study explored the prognostic values of imaging and clinicopathological factors for LR-M and LR-4/5 cHCC-CCA patients, and different survival outcomes were observed among four subgroups after conducting risk stratifications.

KEY POINTS: • Corona enhancement, delayed central enhancement, and MVI were identified as predictors of RFS in cHCC-CCAs which were classified into LR-M. Mosaic architecture, CA19-9, and MVI were independently associated with RFS in cHCC-CCAs which were classified into LR-4/5. • Based on the identified risk factors, LR-M and LR-4/5 cHCC-CCA patients could be stratified into two subgroups respectively, with significantly different RFS and OS. • cHCC-CCA patients from LR-M did not always have worse RFS and OS than those from LR-4/5 in some cases.

来源:Eur Radiol,查看原文。版权归原作者所有。

引用

  1. Wang Y, Zhu GQ, Zhou CW, et al. Risk stratification of LI-RADS M and LI-RADS 4/5 combined hepatocellular cholangiocarcinoma: prognostic values of MR imaging features and clinicopathological factors. Eur Radiol. 2022. PMID: 35316365. doi:10.1007/s00330-022-08691-w

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。